Pieris Pharmaceuticals (PIRS) Stock Price Up 5.6%

Pieris Pharmaceuticals Inc (NASDAQ:PIRS) traded up 5.6% on Thursday . The stock traded as high as $6.30 and last traded at $6.26. 512,897 shares changed hands during trading, a decline of 16% from the average session volume of 614,111 shares. The stock had previously closed at $5.93.

Several equities research analysts have recently weighed in on the company. HC Wainwright set a $9.00 target price on Pieris Pharmaceuticals and gave the stock a “buy” rating in a research report on Monday, October 2nd. ValuEngine lowered Pieris Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, December 1st. One equities research analyst has rated the stock with a sell rating and four have issued a buy rating to the company’s stock. Pieris Pharmaceuticals presently has a consensus rating of “Buy” and a consensus price target of $9.00.

Pieris Pharmaceuticals (NASDAQ:PIRS) last posted its quarterly earnings results on Wednesday, November 8th. The biotechnology company reported ($0.16) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.21) by $0.05. Pieris Pharmaceuticals had a negative return on equity of 221.93% and a negative net margin of 321.83%. The firm had revenue of $3.93 million for the quarter, compared to the consensus estimate of $1.52 million. Pieris Pharmaceuticals’s revenue for the quarter was up 400.3% on a year-over-year basis. sell-side analysts forecast that Pieris Pharmaceuticals Inc will post -0.72 earnings per share for the current year.

In other Pieris Pharmaceuticals news, major shareholder Orbimed Advisors Llc sold 147,635 shares of the business’s stock in a transaction on Monday, December 18th. The stock was sold at an average price of $5.70, for a total transaction of $841,519.50. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 4.05% of the stock is owned by insiders.

Institutional investors and hedge funds have recently bought and sold shares of the business. Voya Investment Management LLC purchased a new stake in Pieris Pharmaceuticals during the second quarter worth $100,000. Wells Fargo & Company MN acquired a new position in shares of Pieris Pharmaceuticals in the third quarter worth $105,000. State of Wisconsin Investment Board acquired a new position in shares of Pieris Pharmaceuticals in the second quarter worth $132,000. The Manufacturers Life Insurance Company raised its holdings in shares of Pieris Pharmaceuticals by 1,106.3% in the second quarter. The Manufacturers Life Insurance Company now owns 31,785 shares of the biotechnology company’s stock worth $161,000 after acquiring an additional 29,150 shares during the last quarter. Finally, Rhumbline Advisers acquired a new position in shares of Pieris Pharmaceuticals in the second quarter worth $184,000. Institutional investors own 50.45% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This story was first reported by Community Financial News and is the property of of Community Financial News. If you are accessing this story on another website, it was illegally stolen and republished in violation of United States and international copyright & trademark laws. The original version of this story can be viewed at https://www.com-unik.info/2017/12/21/pieris-pharmaceuticals-pirs-stock-price-up-5-6.html.

Pieris Pharmaceuticals Company Profile

Pieris Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Its Anticalins proteins are a class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins typically found in blood plasma and other bodily fluids.

Receive News & Ratings for Pieris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit